key: cord-0789877-37n22k87 authors: Anderson, M. C.; Holzmayer, V.; Vallari, A.; Taylor, R.; Moy, J.; Cloherty, G. title: Expanding access to SARS-CoV-2 IgG and IgM serologic testing using fingerstick whole blood, plasma, and rapid lateral flow assays date: 2021-04-18 journal: nan DOI: 10.1101/2021.04.16.21255130 sha: a1e53c0058ba453e306a5fe38c5d44a81e43070d doc_id: 789877 cord_uid: 37n22k87 Serologic testing for SARS-CoV-2 antibodies can be used to confirm diagnosis, estimate seroprevalence, screen convalescent plasma donors, and assess vaccine efficacy. Several logistical and infrastructure challenges limit access to SARS-CoV-2 serologic testing. Dried blood spot (DBS) samples have been used for serology testing of various diseases in resource-limited settings. We examined the use of DBS samples and capillary blood (fingerstick) plasma collected in Microtainer tubes for SARS-CoV-2 testing with the automated Abbott ARCHITECT SARS-CoV-2 IgG (List 6R86) and IgM assays and use of venous whole blood with a prototype PANBIO rapid point-of-care lateral flow SARS-CoV-2 IgG assay. The ARCHITECT SARS-CoV-2 IgG assay was initially optimized for use with DBS, venous and capillary plasma, and venous whole blood collected from patients with symptoms and PCR-confirmed COVID-19 and negative asymptomatic controls. Assay linearity and reproducibility was confirmed with 3 contrived DBS samples, with sample stability and signal recovery after 14 days at room temperature. ARCHITECT SARS-CoV-2 IgG and IgM assay results showed high concordance between fingerstick DBS and venous DBS samples, and between fingerstick DBS and venous whole blood samples (n=61). Discordant results were seen in 3 participants (2 IgG, 1 IgM) who were in the process of seroreversion at the time of sample collection and had results near the assay cutoff. Use of fingerstick plasma collected in Microtainer tubes (n=109) showed 100% concordant results (R2=0.997) with matched patient venous plasma on the ARCHITECT SARS-CoV-2 IgG assay. High concordance of assay results (92.9% positive, 100% negative) was also observed for the PANBIO SARS-CoV-2 IgG assay compared to the ARCHITECT SARS-CoV-2 IgG assay run with matched venous plasma (n=61). Fingerstick DBS and plasma samples are easy and inexpensive to collect and, along with the use of rapid point-of-care testing platforms, will expand access to SARS-CoV-2 serology testing, particularly in resource-limited areas. capillary plasma, and venous whole blood collected from patients with symptoms and PCR-23 confirmed COVID-19 and negative asymptomatic controls. Assay linearity and reproducibility 24 was confirmed with 3 contrived DBS samples, with sample stability and signal recovery after 14 25 days at room temperature. ARCHITECT™ SARS-CoV-2 IgG and IgM assay results showed 26 high concordance between fingerstick DBS and venous DBS samples, and between fingerstick 27 DBS and venous whole blood samples (n=61). Discordant results were seen in 3 participants (2 28 IgG, 1 IgM) who were in the process of seroreversion at the time of sample collection and had 29 results near the assay cutoff. Use of fingerstick plasma collected in Microtainer tubes (n=109) 30 showed 100% concordant results (R 2 =0.997) with matched patient venous plasma on the 31 ARCHITECT™ SARS-CoV-2 IgG assay. High concordance of assay results (92.9% positive, 32 Serologic testing for SARS-CoV-2 antibodies can be used to complement PCR-based 45 diagnostic testing [1] and may assist in identifying asymptomatic cases and those with past 46 infection as potential donors for convalescent plasma therapy. The COVID-19 pandemic has 47 presented unique barriers to achieving widespread serologic testing, such as logistical and 48 infrastructure challenges that limit the number of available testing sites, transportation issues 49 that reduce patient access to existing testing sites, and reluctance among patients to seek out 50 testing in clinical settings that may increase risk of exposure to the virus. In addition, current 51 serologic assays utilize venous whole blood or plasma samples that require trained 52 phlebotomists and sophisticated laboratory equipment. Removing these hurdles would improve 53 access to SARS-CoV-2 serologic testing and expand the ability to track the virus and its 54 community spread. Innovative approaches to expanding SARS-CoV-2 serologic testing include 55 the development of fully automated assay systems to increase testing speed and rapid point-of-56 care testing platforms, as well as the use of new types of samples that can be collected at home 57 or in drive-through settings. 58 In low-and middle-income countries (LMICs) that lack capacity for venous blood draws or 59 where transporting and storing blood samples is difficult, the use of dried blood spot (DBS) 60 samples has improved access to diagnostic testing for various infectious diseases After providing informed consent, up to 12 mL of EDTA venous whole blood was collected from 119 each study participant (n=61) along with fingerstick whole blood. Five separate DBS samples 120 were generated from fingerstick whole blood, and another five DBS samples were generated 121 from venous whole blood. Plasma was separated using 6 mL of venous whole blood and the 122 remaining 6 mL of venous whole blood was stored at -80°C. Deidentified plasma, whole blood, 123 and DBS samples were frozen at -80°C and shipped to Abbott Diagnostics (Abbott Park, IL) for 124 use in serological assays. To evaluate the clinical performance of the IgG and IgM assays using 125 DBS samples, for each participant, assay results were compared for venous whole blood DBS, 126 fingerstick whole blood DBS, and venous plasma as the gold standard. 127 All samples were run on the Abbott ARCHITECT i2000SR instrument using the EUA-approved 130 SARS-CoV-2 IgG (List 6R86) assay and prototype SARS-CoV-2 IgM assay (Abbott Diagnostics, 131 Abbott Park, IL) per the ARCHITECT operations manual and assay package insert instructions, 132 with volume modifications for the DBS samples based on optimization experiments. The 133 qualitative SARS-CoV-2 IgG and IgM assays use chemiluminescent microparticles to detect IgG 134 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) For assay volume optimization and stability studies, venous plasma from a commercially 142 available SARS-CoV-2 IgG-positive patient was serially diluted in negative whole blood. DBS 143 samples were generated by pipetting 70 µL of each whole blood dilution to the center of a 12-144 mm Whatman 903 (GE Healthcare/LabMate) DBS card (5 replicate spots/card) and dried 145 overnight in a sterile hood. DBS samples were then cut/punched out and placed in a 1.5-mL 146 Eppendorf tube to which 300 µL elution buffer (1X PBS pH 7.4, 0.25% Triton X-100) was added. 147 The tubes were placed on a shaker for 1 hour at room temperature, and the eluate was then 148 transferred into a fresh 2mL cryogenic tube. The Whatman paper was squeezed to transfer as 149 much liquid as possible to the new tube. The samples were centrifuged for 2 minutes at 10,000 150 RCF before placement on the ARCHITECT i2000SR and run with the SARS-CoV-2 IgG or IgM 151 Assay linearity and stability were assessed using contrived DBS samples generated from 3 153 different commercially available SARS-CoV-2 IgG-positive patients. DBS cards were placed in 154 plastic bags (Minigrip, LabMate) with 1 g silica gel desiccant (Uline) and stored at -20°C, room 155 temperature, or 37°C in an incubator. After 1, 3, 7, 10, and 14 days, the DBS samples were 156 eluted in 300 µl ABT elution buffer and 150 µL of the eluate was run on the ARCHITECT SARS-157 CoV-2 IgG assay. 158 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) A commercially available SARS-CoV-2 IgG positive plasma sample (Sample 1) was serially 165 diluted from 1:5 to 1:100 into negative whole blood. DBS were generated by pipetting 70 µl of 166 each dilution onto Whatman 903 paper and left to dry overnight. DBS were eluted and run with 167 modified SARS-CoV-2 IgG assay parameters to assess signal recovery at various sample 168 volume inputs ( Figure 1A) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted April 18, 2021. ; https://doi.org/10.1101/2021.04.16.21255130 doi: medRxiv preprint and Samples 2 and 3 (Supplemental Figure 1A) . . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted April 18, 2021. shown to be reproducible across all 3 samples ( Figure 1C and Supplemental Figure 1B and 37°C at 1, 3, 7, 10, and 14-day intervals ( . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 18, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 18, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Table 2 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 18, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 18, 2021. Of note, discordant reported results occurred in 2 participants who each had a previous positive Table 3 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 18, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 18, 2021. ; https://doi.org/10.1101/2021.04.16.21255130 doi: medRxiv preprint Similar to the SARS-CoV-2 IgG assay, the single discordant venous DBS sample was from a 282 seroreverting patient whose SARS-CoV-2 IgM plasma index was 0.96, near the assay cutoff. (Table 2) . 292 One of the two discordant samples was from a study participant who had an ARCHITECT index 296 of 1.46, which is near the assay cutoff. 297 A total of 109 participants provided informed consent to have up to 15 ml of venous blood drawn 300 and receive a fingerstick to generate matched venous and fingerstick plasma samples collected 301 in Vacutainer and Microtainer tubes, respectively. One participant was excluded due to 302 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Correlation between SARS-CoV-2 IgG index values from fingerstick and venous plasma was 313 high (R 2 = 0.997), and index interpretation concordance was 100% (108/108), demonstrating 314 equivalency between plasma obtained from fingerstick or venous sources. 315 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) We investigated different methods to expand and improve access to SARS-CoV-2 antibody 318 testing using sample types that require less processing and handling (DBS, Microtainer plasma, 319 and whole blood) than current methods that use venous plasma and require trained 320 phlebotomists. Our results confirm the feasibility of using DBS as starting material for SARS-321 CoV-2 IgG and IgM detection on the automated ARCHITECT platform. We found good 322 concordance between the DBS and venous plasma index values on the ARCHITECT SARS-323 CoV-2 IgG and IgM assays. SARS-CoV-2 IgG DBS samples had higher background in known 324 negative samples, but the results were below the index threshold. Future experiments with 325 different elution conditions will be conducted to further optimize background reduction. 326 Importantly, DBS samples generated from whole venous blood and from fingerstick blood 327 produced concordant assay results, and DBS samples were stable for 2 weeks at room 328 temperature and 1 week at 37°C. Notably, two participants had negative IgG assay results for 329 venous plasma but positive results with DBS samples. The 2 participants with discordant 330 plasma and DBS IgG results and one participant with discordant IgM results had previous 331 positive PCR and IgG results and were found to be in the process of seroreversion at the time 332 the sample used in this study was collected. Thus, these are not false positives with the DBS 333 sample type and may in fact illustrate an increased sensitivity of the DBS assay relative to the 334 plasma assay with the assays' index value cutoffs. These findings have important implications 335 for expanding access to SARS-CoV-2 serologic testing to areas with low capacity for venous 336 blood draws or lack of refrigerated sample storage. 337 Our findings are consistent with previous reports on the utility of DBS samples for SARS-CoV-2 338 serologic testing. Thevis et al. recently described the use of 20 µL capillary blood DBS, collected 339 by fingerstick from 28 participants, 16 of whom had a positive diagnosis by PCR-based testing, 340 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Antibody 396 tests for identification of current and past infection with SARS-CoV-2 Tests for the Diagnosis and Therapeutic Monitoring of HIV and Viral Hepatitis B and C. Front 400 Diagnostic accuracy of 402 serological diagnosis of hepatitis C and B using dried blood spot samples (DBS): two systematic 403 reviews and meta-analyses Immunodeficiency Virus Serological Markers in Samples Collected as HemaSpot and Whatman 406 903 Dried Blood Spots Evaluation of dried blood spot samples for screening of hepatitis C and human 409 immunodeficiency virus in a real-world setting Comparison of fingerstick 412 versus venipuncture for antibody testing of measles and rubella Rubella IgG antibody detection by ELISA using capillary blood 415 samples collected on filter paper and in microtainer tubes Performance 418 characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and seroprevalence in Boise Clinical 421 performance of two SARS-CoV-2 serologic assays Performance characteristics of four high-424 throughput immunoassays for detection of IgG antibodies against SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood from the San Francisco Bay 428 Profiling early humoral response to 430 Infectious Diseases Society of America